Research
Hormonal
Obesity contributes to cardiovascular disease (CVD) through mechanisms including adipose tissue dysfunction, ectopic fat deposition, and altered adipokine secretion (e.g., increased leptin, decreased adiponectin), leading to hypertension, atherosclerosis, and heart failure.
Obesity increases your risk for heart disease and stroke through biological processes like inflammation and hormone imbalance. Maintaining a healthy weight can reduce this risk by mitigating these specific biological factors.
StrongSupportsHIGH confidence
Clinical trials and epidemiological studies have shown that obesity can increase the risk of CVDs... Obesity leads to adipose tissue hypertrophy, dysfunction and inflammation, which ultimately change the structure and function of the cardiovascular system... Adipokines are considered to be a link between obesity and CVD.
Why this rating
Supported by multiple clinical trials and epidemiological studies cited in the review.
Source
Pathophysiology of obesity and its associated diseases
Xin Jin et al. · Acta Pharmaceutica Sinica B · 2023
DOI 10.1016/j.apsb.2023.01.012
narrative_reviewCited 427×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity drives insulin resistance and type 2 diabetes through the accumulation of free fatty acids and pro-inflammatory cytokines in non-adipose tissues, which activate kinases (PKC, JNK, IKKβ) that inhibit insulin receptor signaling.Strong
- Obesity increases the risk of various cancers (e.g., breast, colorectal, liver) through mechanisms involving chronic inflammation, oxidative stress, and altered adipokine secretion (e.g., increased leptin, decreased adiponectin).Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →